
Vaxcyte Inc
NASDAQ:PCVX

Fundamental Analysis


Revenue & Expenses Breakdown
Vaxcyte Inc
Balance Sheet Decomposition
Vaxcyte Inc
Current Assets | 1.8B |
Cash & Short-Term Investments | 1.7B |
Other Current Assets | 40.8m |
Non-Current Assets | 1.7B |
Long-Term Investments | 1.4B |
PP&E | 270.1m |
Other Non-Current Assets | 65.7m |
Free Cash Flow Analysis
Vaxcyte Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Vaxcyte Inc
Revenue
|
0
USD
|
Operating Expenses
|
-569.5m
USD
|
Operating Income
|
-569.5m
USD
|
Other Expenses
|
105.6m
USD
|
Net Income
|
-463.9m
USD
|
PCVX Profitability Score
Profitability Due Diligence
Vaxcyte Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Score
Vaxcyte Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
PCVX Solvency Score
Solvency Due Diligence
Vaxcyte Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Vaxcyte Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PCVX Price Targets Summary
Vaxcyte Inc
According to Wall Street analysts, the average 1-year price target for
PCVX
is 140.99 USD
with a low forecast of 90.9 USD and a high forecast of 171.15 USD.
Dividends
Current shareholder yield for PCVX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?